Hypothesis II: The majority of VLDL-apoB48 remnants in postprandial plasma are derived from the liver, not from the intestine.

Chylomicrons (CM) Fat intake Postprandial plasma Remnant lipoproteins (RLP) Very low density lipoproteins (VLDL) apoB100 apoB48

Journal

Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 19 10 2018
revised: 10 12 2018
accepted: 10 12 2018
pubmed: 17 12 2018
medline: 23 3 2019
entrez: 17 12 2018
Statut: ppublish

Résumé

We have long thought that remnant lipoproteins (RLP) in the postprandial plasma contain CM remnants (exogenous remnants; RLP-apoB48) and VLDL remnants (endogenous remnants; RLP-apoB100) of different origin, i.e. produced in the intestine and liver, respectively. However, the majority of CM remnants incorporated into liver from the circulation are degraded in liver and may be reused for the remodeling of VLDL. Namely, the most of the apoB48 in CM remnants are smoothly incorporated into the liver after fat intake along with lipids and other apolipoproteins via the LDL receptor and LDL-receptor-related protein (LRP). Subsequently, apoB48 may be reconstituted in VLDL as VLDL apoB48 through an essential physiological pathway similar or the same to that of VLDL apoB100 formation in the liver and secreted into the circulation as VLDL apoB48 to form their remnants. Because those particles are newly reconstituted in liver as a portion of VLDL, we propose that both RLP-apoB100 and RLP-apoB48 are endogenous VLDL remnants produced in liver after fat intake. Also we predict the presence of a new pathway for the formation of VLDL apoB48 along with VLDL apoB100 in liver in humans similar in mice and rats.

Identifiants

pubmed: 30553860
pii: S0009-8981(18)30641-7
doi: 10.1016/j.cca.2018.12.010
pii:
doi:

Substances chimiques

Apolipoprotein B-48 0
Lipoproteins, VLDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-16

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Katsuyuki Nakajima (K)

Laboratory of Clinical Nutrition and Medicine, Kagawa Nutrition University, Tokyo, Japan; Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan. Electronic address: nakajimak05@ybb.ne.jp.

Yoshiharu Tokita (Y)

Laboratory of Clinical Nutrition and Medicine, Kagawa Nutrition University, Tokyo, Japan; Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan.

Akira Tanaka (A)

Laboratory of Clinical Nutrition and Medicine, Kagawa Nutrition University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH